Possible modification of BRSK1 on the risk of alkylating
chemotherapy-related reduced ovarian function

J 2021

Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function

VAN DER KOOI, A. L. L. F., M. VAN DIJK, L. BROER, M. H. VAN DEN BERG, J. S. E . LAVEN et. al.

Základní údaje

Originální název

Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function

Autoři

VAN DER KOOI, A. L. L. F. (garant), M. VAN DIJK, L. BROER, M. H. VAN DEN BERG, J. S. E . LAVEN, F. E. VAN LEEUWEN, C. B. LAMBALK, A. OVERBEEK, J. J . LOONEN, H. J. VAN DER PAL, W. J. TISSING, B. VERSLUYS, D. BRESTERS, C. C. M. BEERENDONK, C. R. RONCKERS, M. VAN DER HEIDEN-VAN DER LOO, G. L. KASPERS, A. C. H. DE VRIES, L. L. ROBISON, M. M. HUDSON, W. CHEMAITILLY, J. BYRNE, C. BERGER, E. CLEMENS, U. DIRKSEN, J. F. WINTHER, S. D. FOSSA, D. GRABOW, R. HAUPT, M. KAISER, Tomáš KEPÁK (203 Česká republika, domácí), J. KRUSEOVA, D. MODAN-MOSES, S. M. F. PLUIJM, C. SPIX, O. ZOLK, P. KAATSCH, J. H. KRIJTHE, L. C. KREMER, Y. YASUI, R. J. BROOKE, A. G. UITTERLINDEN, M. M. VAN DEN HEUVEL-EIBRINK a E. VAN DULMEN-DEN BROEDER

Vydání

Human Reproduction, Oxford, Oxford Journals, 2021, 0268-1161

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30214 Obstetrics and gynaecology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.353

Kód RIV

RIV/00216224:14110/21:00122128

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1093/humrep/deaa342

UT WoS

000648942000029

Klíčová slova anglicky

ovarian reserve; childhood cancer; survivorship; fertility; gonadotoxicity

Štítky

14110321, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 8. 2021 12:00, Mgr. Tereza Miškechová

Anotace

V originále

STUDY QUESTION: Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)? SUMMARY ANSWER: Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy. WHAT IS KNOWN ALREADY: Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian function might explain this variability. STUDY DESIGN, SIZE, DURATION: CCS for the discovery cohort were identified from the Dutch Childhood Oncology Group (DCOG) LATER VEVO-study, a multi-centre retrospective cohort study evaluating fertility, ovarian reserve and risk of premature menopause among adult female 5-year survivors of childhood cancer. Female 5-year CCS, diagnosed with cancer and treated with chemotherapy before the age of 25 years, and aged 18 years or older at time of study were enrolled in the current study. Results from the discovery Dutch DCOG-LATER VEVO cohort (n = 285) were validated in the pan-European PanCareLIFE (n =465) and the USA-based St. Jude Lifetime Cohort (n = 391). PARTICIPANTS/MATERIALS, SETTING, METHODS: To evaluate ovarian function, anti-Miillerian hormone (AMH) levels were assessed in both the discovery cohort and the replication cohorts. Using additive genetic models in linear and logistic regression, five genetic variants involved in DNA damage response were analysed in relation to cyclophosphamide equivalent dose (CED) score and their impact on ovarian function. Results were then examined using fixed-effect meta-analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Meta-analysis across the three independent cohorts showed a significant interaction effect (P= 3.0 x 10(-4)) between rs11668344 of BRSK 1 (allele frequency = 0.34) among CCS treated with high-dose alkylating agents (CED score >= 8000 mg/m(2)), resulting in a 2.5-fold increased odds of a reduced ovarian function (lowest AMH tertile) for CCS carrying one G allele compared to CCS without this allele (odds ratio genotype AA: 2.01 vs AG: 5.00). LIMITATIONS, REASONS FOR CAUTION: While low AMH levels can also identify poor responders in assisted reproductive technology, it needs to be emphasized that AMH remains a surrogate marker of ovarian function. WIDER IMPLICATIONS OF THE FINDINGS: Further research, validating our findings and identifying additional risk contributing genetic variants, may enable individualized counselling regarding treatment-related risks and necessity of fertility preservation procedures in girls with cancer.

Citovat

VAN DER KOOI, A. L. L. F., M. VAN DIJK, L. BROER, M. H. VAN DEN BERG, J. S. E . LAVEN, F. E. VAN LEEUWEN, C. B. LAMBALK, A. OVERBEEK, J. J . LOONEN, H. J. VAN DER PAL, W. J. TISSING, B. VERSLUYS, D. BRESTERS, C. C. M. BEERENDONK, C. R. RONCKERS, M. VAN DER HEIDEN-VAN DER LOO, G. L. KASPERS, A. C. H. DE VRIES, L. L. ROBISON, M. M. HUDSON, W. CHEMAITILLY, J. BYRNE, C. BERGER, E. CLEMENS, U. DIRKSEN, J. F. WINTHER, S. D. FOSSA, D. GRABOW, R. HAUPT, M. KAISER, Tomáš KEPÁK, J. KRUSEOVA, D. MODAN-MOSES, S. M. F. PLUIJM, C. SPIX, O. ZOLK, P. KAATSCH, J. H. KRIJTHE, L. C. KREMER, Y. YASUI, R. J. BROOKE, A. G. UITTERLINDEN, M. M. VAN DEN HEUVEL-EIBRINK a E. VAN DULMEN-DEN BROEDER. Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function. Human Reproduction. Oxford: Oxford Journals, 2021, roč. 36, č. 4, s. 1120-1133. ISSN 0268-1161. Dostupné z: https://dx.doi.org/10.1093/humrep/deaa342.

@article{1786881,
   author = {Van der Kooi, A. L. L. F. and Van Dijk, M. and Broer, L. and Van den Berg, M. H. and Laven, J. S. E . and Van Leeuwen, F. E. and Lambalk, C. B. and Overbeek, A. and Loonen, J. J . and van der Pal, H. J. and Tissing, W. J. and Versluys, B. and Bresters, D. and Beerendonk, C. C. M. and Ronckers, C. R. and Van der Heidenandvan der Loo, M. and Kaspers, G. L. and De Vries, A. C. H. and Robison, L. L. and Hudson, M. M. and Chemaitilly, W. and Byrne, J. and Berger, C. and Clemens, E. and Dirksen, U. and Winther, J. F. and Fossa, S. D. and Grabow, D. and Haupt, R. and Kaiser, M. and Kepák, Tomáš and Kruseova, J. and ModanandMoses, D. and Pluijm, S. M. F. and Spix, C. and Zolk, O. and Kaatsch, P. and Krijthe, J. H. and Kremer, L. C. and Yasui, Y. and Brooke, R. J. and Uitterlinden, A. G. and Van den HeuvelandEibrink, M. M. and Van Dulmenandden Broeder, E.},
   article_location = {Oxford},
   article_number = {4},
   doi = {http://dx.doi.org/10.1093/humrep/deaa342},
   keywords = {ovarian reserve; childhood cancer; survivorship; fertility; gonadotoxicity},
   language = {eng},
   issn = {0268-1161},
   journal = {Human Reproduction},
   title = {Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function},
   url = {https://academic.oup.com/humrep/article/36/4/1120/6134861},
   volume = {36},
   year = {2021}
}

TY  - JOUR
ID  - 1786881
AU  - Van der Kooi, A. L. L. F. - Van Dijk, M. - Broer, L. - Van den Berg, M. H. - Laven, J. S. E . - Van Leeuwen, F. E. - Lambalk, C. B. - Overbeek, A. - Loonen, J. J . - van der Pal, H. J. - Tissing, W. J. - Versluys, B. - Bresters, D. - Beerendonk, C. C. M. - Ronckers, C. R. - Van der Heiden-van der Loo, M. - Kaspers, G. L. - De Vries, A. C. H. - Robison, L. L. - Hudson, M. M. - Chemaitilly, W. - Byrne, J. - Berger, C. - Clemens, E. - Dirksen, U. - Winther, J. F. - Fossa, S. D. - Grabow, D. - Haupt, R. - Kaiser, M. - Kepák, Tomáš - Kruseova, J. - Modan-Moses, D. - Pluijm, S. M. F. - Spix, C. - Zolk, O. - Kaatsch, P. - Krijthe, J. H. - Kremer, L. C. - Yasui, Y. - Brooke, R. J. - Uitterlinden, A. G. - Van den Heuvel-Eibrink, M. M. - Van Dulmen-den Broeder, E.
PY  - 2021
TI  - Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function
JF  - Human Reproduction
VL  - 36
IS  - 4
SP  - 1120-1133
EP  - 1120-1133
PB  - Oxford Journals
SN  - 02681161
KW  - ovarian reserve
KW  - childhood cancer
KW  - survivorship
KW  - fertility
KW  - gonadotoxicity
UR  - https://academic.oup.com/humrep/article/36/4/1120/6134861
N2  - STUDY QUESTION: Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)? SUMMARY ANSWER: Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy. WHAT IS KNOWN ALREADY: Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian function might explain this variability. STUDY DESIGN, SIZE, DURATION: CCS for the discovery cohort were identified from the Dutch Childhood Oncology Group (DCOG) LATER VEVO-study, a multi-centre retrospective cohort study evaluating fertility, ovarian reserve and risk of premature menopause among adult female 5-year survivors of childhood cancer. Female 5-year CCS, diagnosed with cancer and treated with chemotherapy before the age of 25 years, and aged 18 years or older at time of study were enrolled in the current study. Results from the discovery Dutch DCOG-LATER VEVO cohort (n = 285) were validated in the pan-European PanCareLIFE (n =465) and the USA-based St. Jude Lifetime Cohort (n = 391). PARTICIPANTS/MATERIALS, SETTING, METHODS: To evaluate ovarian function, anti-Miillerian hormone (AMH) levels were assessed in both the discovery cohort and the replication cohorts. Using additive genetic models in linear and logistic regression, five genetic variants involved in DNA damage response were analysed in relation to cyclophosphamide equivalent dose (CED) score and their impact on ovarian function. Results were then examined using fixed-effect meta-analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Meta-analysis across the three independent cohorts showed a significant interaction effect (P= 3.0 x 10(-4)) between rs11668344 of BRSK 1 (allele frequency = 0.34) among CCS treated with high-dose alkylating agents (CED score >= 8000 mg/m(2)), resulting in a 2.5-fold increased odds of a reduced ovarian function (lowest AMH tertile) for CCS carrying one G allele compared to CCS without this allele (odds ratio genotype AA: 2.01 vs AG: 5.00). LIMITATIONS, REASONS FOR CAUTION: While low AMH levels can also identify poor responders in assisted reproductive technology, it needs to be emphasized that AMH remains a surrogate marker of ovarian function. WIDER IMPLICATIONS OF THE FINDINGS: Further research, validating our findings and identifying additional risk contributing genetic variants, may enable individualized counselling regarding treatment-related risks and necessity of fertility preservation procedures in girls with cancer.
ER  -

VAN DER KOOI, A. L. L. F., M. VAN DIJK, L. BROER, M. H. VAN DEN BERG, J. S. E . LAVEN, F. E. VAN LEEUWEN, C. B. LAMBALK, A. OVERBEEK, J. J . LOONEN, H. J. VAN DER PAL, W. J. TISSING, B. VERSLUYS, D. BRESTERS, C. C. M. BEERENDONK, C. R. RONCKERS, M. VAN DER HEIDEN-VAN DER LOO, G. L. KASPERS, A. C. H. DE VRIES, L. L. ROBISON, M. M. HUDSON, W. CHEMAITILLY, J. BYRNE, C. BERGER, E. CLEMENS, U. DIRKSEN, J. F. WINTHER, S. D. FOSSA, D. GRABOW, R. HAUPT, M. KAISER, Tomáš KEPÁK, J. KRUSEOVA, D. MODAN-MOSES, S. M. F. PLUIJM, C. SPIX, O. ZOLK, P. KAATSCH, J. H. KRIJTHE, L. C. KREMER, Y. YASUI, R. J. BROOKE, A. G. UITTERLINDEN, M. M. VAN DEN HEUVEL-EIBRINK a E. VAN DULMEN-DEN BROEDER. Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function. \textit{Human Reproduction}. Oxford: Oxford Journals, 2021, roč.~36, č.~4, s.~1120-1133. ISSN~0268-1161. Dostupné z: https://dx.doi.org/10.1093/humrep/deaa342.

Podrobný výpis o publikaci